Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
'),o.close()}("https://assets.zendesk.com/embeddable_framework/main.js","jmir.zendesk.com");/*]]>*/

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: Journal of Medical Internet Research

Date Submitted: Mar 13, 2024
Open Peer Review Period: Mar 15, 2024 - May 10, 2024
(currently open for review)

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

We Can Do This: A web-based therapeutic program for reducing methamphetamine use -amongst Aboriginal and Torres Strait Islander people: Findings from a wait-list control, randomised trial

  • Rachel Reilly; 
  • Rebecca McKetin; 
  • Federica Barzi; 
  • Tayla Degan; 
  • Nadine Ezard; 
  • Kate Conigrave; 
  • Julia Butt; 
  • Yvette Roe; 
  • Handan Wand; 
  • Brendan Quinn; 
  • Wade Longbottom; 
  • Carla Treloar; 
  • Adrian Dunlop; 
  • James Ward

ABSTRACT

Background:

Digital interventions can help to overcome barriers to care including stigma, geographical distance and a lack of culturally appropriate treatment options. We Can Do This was a web-app designed with input from cultural advisors and end-users to support Aboriginal and Torres Strait Islander people seeking to stop or reduce their use of methamphetamine and increase psychosocial wellbeing.

Objective:

We sought to evaluate the effectiveness of the web-app via a wait-list control, randomised trial

Methods:

Aboriginal and Torres Strait Islander people aged 16 or over who self-identified as having used methamphetamine weekly for the past three months were invited to participate online. Following a baseline survey, participants were randomised to either the intervention group, who could access the web-app for six weeks, or the control group, who received harm-minimisation material. Participants repeated the survey at one, two and three months post-baseline. We hypothesized that the intervention group would have significantly reduced frequency of use at three-month follow-up. Secondary outcomes included help-seeking, psychosocial distress and days spent out of usual role due to methamphetamine use.

Results:

Participants at baseline were 210 Aboriginal and/or Torres Strait Islander men and women aged 16 or over. Methamphetamine use declined significantly in all participants who completed three-month follow-up, however there were no significant differences between intervention and control groups on the primary or secondary outcomes.

Conclusions:

Drop out and a lack of sustained engagement hindered our ability to evaluate the effectiveness of the web-app. Nonetheless, the trial gleaned some useful lessons relating to recruitment and engagement in web-apps. Clinical Trial: Australian New Zealand Clinical Trials Registry ACTRN12619000134123p; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376088&isReview=true


 Citation

Please cite as:

Reilly R, McKetin R, Barzi F, Degan T, Ezard N, Conigrave K, Butt J, Roe Y, Wand H, Quinn B, Longbottom W, Treloar C, Dunlop A, Ward J

We Can Do This: A web-based therapeutic program for reducing methamphetamine use -amongst Aboriginal and Torres Strait Islander people: Findings from a wait-list control, randomised trial

JMIR Preprints. 13/03/2024:58341

DOI: 10.2196/preprints.58341

URL: https://preprints.jmir.org/preprint/58341

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.

Advertisement